The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
What Will Be The Estimated Market Valuation Of The Histone Deacetylase Inhibitors Market By The End Of 2030?
The market for histone deacetylase inhibitors has demonstrated robust expansion over recent years. This market is projected to expand from $1.29 billion in 2025 to $1.39 billion in 2026, achieving a compound annual growth rate (CAGR) of 7.6%. Historically, this expansion has been driven by factors such as the initial efficacy of HDAC inhibitors in treating blood cancers, a deeper comprehension of epigenetic regulation in various diseases, the introduction of approved first-generation HDAC inhibitors, the development of cancer research facilities, and increased financial commitment to therapies targeting cancer.
The histone deacetylase inhibitors market is set to experience robust expansion in the coming years, with projections indicating a rise to $1.81 billion by 2030, driven by a compound annual growth rate (CAGR) of 6.8%. This growth during the forecast period is attributed to the escalating global incidence of cancer, an expanding pipeline of epigenetic-based treatments, a heightened focus on precision oncology methodologies, the proliferation of clinical trials for neurological and inflammatory conditions, and the demand for more selective and safer epigenetic pharmaceuticals. Significant trends anticipated for this period include the increased incorporation of HDAC inhibitors into oncology treatment plans, a growing emphasis on selective and isoform-specific HDAC inhibitors, the rising adoption of combination therapies involving HDAC inhibitors, the extension of HDAC inhibitor research beyond oncological applications, and a steady increase in oral HDAC inhibitor formulations.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=17170&type=smp
What Primary Drivers Are Shaping The Development Of The Histone Deacetylase Inhibitors Market?
The rising incidence of cancer is anticipated to propel the future growth of the histone deacetylase inhibitors market. This increase in cancer cases is primarily attributed to aging populations, heightened exposure to risk factors such as tobacco, diet, and environmental pollutants, and improved diagnostic techniques enabling earlier and more frequent detection. Histone deacetylase inhibitors treat cancer by altering chromatin structure, leading to the activation of tumor suppressor genes and suppression of oncogenes, thereby inducing cell cycle arrest and apoptosis in cancer cells. For instance, in February 2024, according to the World Health Organization, a US-based intergovernmental organization, approximately 35 million new cancer cases were predicted in 2050, a 77% increase from the estimated 20 million cases in 2022. Therefore, the growing incidence of cancer is driving the expansion of the histone deacetylase inhibitors market.
Which Segment Classifications Shape The Histone Deacetylase Inhibitors Market?
The histone deacetylase inhibitors market covered in this report is segmented –
1) By Classification: Class I Histone Deacetylases (HDACs), Class II Histone Deacetylases (HDACs), Class III Histone Deacetylases (HDACs), Other Classifications
2) By Route Of Administration: Oral, Injectable, Other Routes Of Administration
3) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy, Other Distribution Channels
4) By Application: Oncology, Neurology, Other Applications
5) By End Users: Hospitals, Homecare, Specialty Clinics, Other End Users
Subsegments:
1) By Class I Histone Deacetylases (HDACs): HDAC1 Inhibitors, HDAC2 Inhibitors, HDAC3 Inhibitors, HDAC8 Inhibitors
2) By Class II Histone Deacetylases (HDACs): HDAC4 Inhibitors, HDAC5 Inhibitors, HDAC6 Inhibitors, HDAC7 Inhibitors, HDAC9 Inhibitors, HDAC10 Inhibitors
3) By Class III Histone Deacetylases (HDACs): Sirtuin 1 (SIRT1) Inhibitors, Sirtuin 2 (SIRT2) Inhibitors, Sirtuin 3 (SIRT3) Inhibitors, Sirtuin 4 (SIRT4) Inhibitors, Sirtuin 5 (SIRT5) Inhibitors, Sirtuin 6 (SIRT6) Inhibitors, Sirtuin 7 (SIRT7) Inhibitors
4) By Other Classifications: Dual-acting HDAC Inhibitors, Pan-HDAC Inhibitors, Selective HDAC Inhibitors, Combination Inhibitors (HDAC + Other Mechanisms)
How Are Trends Impacting The Histone Deacetylase Inhibitors Market?
Major entities within the histone deacetylase inhibitors market are prioritizing the creation of innovative product formulations, such as oral histone deacetylase (HDAC) inhibitors, aimed at broadening therapeutic possibilities and enhancing patient convenience and adherence. An oral histone deacetylase (HDAC) inhibitor is an orally administered medication that targets HDAC enzymes involved in gene regulation, showing potential utility in addressing various ailments, including cancer and inflammatory conditions. For instance, in March 2024, Italfarmaco S.p.A., an Italy-based pharmaceutical firm, secured Food and Drug Administration approval for Duvyzat (givinostat), an oral histone deacetylase (HDAC) inhibitor, intended for the treatment of Duchenne muscular dystrophy (DMD) in patients aged 6 years and older. Duvyzat functions as a histone deacetylase (HDAC) inhibitor by ameliorating the sequence of occurrences contributing to muscle damage, thereby potentially retarding the advancement of muscle deterioration linked with DMD. Its mechanism involves curbing HDAC overactivity, which diminishes inflammation and fibrosis while stimulating muscle fiber regeneration. The aforementioned approval stemmed from the pivotal phase 3 EPIDYS trial, which successfully achieved its primary endpoint by demonstrating that individuals receiving Duvyzat exhibited a statistically significant reduction in the duration required to complete the four-stair climb assessment when contrasted with those on a placebo.
Which Companies Are Expanding Their Footprint In The Histone Deacetylase Inhibitors Market?
Major companies operating in the histone deacetylase inhibitors market are Syndax Pharmaceuticals Inc., MEI Pharma Inc., Italfarmaco S.p.A., Shenzhen Chipscreen Biosciences Co. Ltd., Celgene Corporation, Spectrum Pharmaceuticals Inc., Curis Inc., Onxeo SA, Celleron Therapeutics, Forum Pharmaceuticals Inc., Merck & Co. Inc., AstraZeneca plc, Novartis AG, Eisai Co. Ltd., Karyopharm Therapeutics Inc., Medivir AB, Huya Bioscience International LLC, Crystal Genomics Inc., Midatech Pharma PLC, Regenacy Pharmaceuticals Inc.
Read the full histone deacetylase inhibitors market report here:
How Does The Histone Deacetylase Inhibitors Market Perform Across Major Global Regions?
North America was the largest region in the histone deacetylase inhibitors market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the histone deacetylase inhibitors market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Histone Deacetylase Inhibitors Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=17170&type=smp
Browse Through More Reports Similar to the Global Histone Deacetylase Inhibitors Market 2026, By The Business Research Company
Histone Deacetylase Inhibitors Market Report 2026
Histone Deacetylase Inhibitors Market Report 2026
Enzyme Inhibitor Market Report 2026
https://www.thebusinessresearchcompany.com/report/enzyme-inhibitor-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model